Ortin Laboratories Ltd Stock Analysis

BSE: 539287 | NSE: ORTINLAB | Pharmaceuticals & Drugs | Small Cap

BSE Share Price Jan 18, 18:01
35.10 0.75 (2.18%)

DeciZen - Make an Informed Decision on Ortin Laboratories

M-Cap below 100cr DeciZen not available

10 Year X-Ray of Ortin Laboratories:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide
Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
ROCE % 11.3%9.9%9.5%8%7.3%5.8%7.3%8.2%3.9%5.1%-
Value Creation Index -0.2-0.3-0.3-0.4-0.5-0.6-0.5-0.4-0.7NA-

Growth Parameters

Growth Parameters Colour Code Guide
Sales 85.874.867.160.462.966.879.71681978.258
YoY Gr. Rt. %--12.8%-10.3%-10%4.2%6.1%19.4%110.5%17.7%-95.9%-
Adj EPS 0.80.60.70.50.50.20.30.8-0.31.21.9
YoY Gr. Rt. %--19%9.4%-24.3%-9.4%-50%37.5%127.3%-142.7%NA-
BVPS (₹) 11.912.31313.313.713.814.214.814.11414.2
Adj Net Profit 1.31.11.20.90.80.40.61.3-0.612
Cash Flow from Ops. 0.3-1.7-1.8-1.40.51.91.66.53.318-
Debt/CF from Ops. 44.5-10.8-10.6-15.240.48.911.135.90.4-

CAGR

CAGR Colour Code Guide
9 Years 5 Years 3 Years 1 Years
Sales -23%-33.5%-53.2%-95.9%
Adj EPS 4.4%19.3%52.1%NA
BVPS 1.80.3-0.6-0.6
Share Price 3.6% 11.8% 31.3% 13.4%

Key Financial Parameters

Performance Ratio Colour Code Guide
Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity % 6.75.35.54.13.51.82.45.2-2.25.413.5
Op. Profit Mgn % 8.28.89.110.49.486.93.72.915.35.2
Net Profit Mgn % 1.61.51.81.51.30.60.70.8-0.311.62.7
Debt to Equity 0.70.90.90.90.90.70.70.80.80.60.1
Working Cap Days 1812392392592352232051441592,175273
Cash Conv. Cycle 1021508511712711861512630

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 13.50%

Net Profit is growing at healthy rate in last 3 years 52.05%

Debt to equity has declined versus last 3 years average to 0.61

Sales growth has been subdued in last 3 years -53.20%

Sales growth is not so good in last 4 quarters at -74.11%

Latest Financials - Ortin Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 1.9 -
TTM Sales (₹ Cr.) 57.8 -
BVPS (₹.) 14.2 -
Reserves (₹ Cr.) 3 -
P/BV 2.43 -
PE 18.09 -
From the Market
52 Week Low / High (₹) 21.65 / 52.25
All Time Low / High (₹) 6.60 / 52.25
Market Cap (₹ Cr.) 27.9
Equity (₹ Cr.) 8.1
Face Value (₹) 10
Industry PE 40.9

Management X-Ray of Ortin Laboratories :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Analyst's Notes

News

About Ortin Laboratories Ltd

Ortin Laboratories established in the year 1986  was a private limited company with a nominal capital of Rs 1 lakh to offer quality drugs and medicines to the suffering mankind. Later, in the year 1994, this private limited company converted as a public limited company with 5,060 shareholders which received good subscription from the public. These proceeds were utilised for constructing a factory in a spacious area of 25000 sq feet with all ultra-modern infrastructure as per the WHO GMP Standards to manufacture the complete range of Pharmaceutical Formulations of Tablets, Capsules, Syrups, Dry Powders & Ointments. Due to its concern for quality, the company stands as a leading and predominant pharmaceutical manufacturer of drugs and medicines of the country with turnover running in crores of rupees.

Quality is the hallmark of Ortin. At every stage of production from raw material to finished products, highest standard of quality is ensured with the help of most modern equipment and experienced personnel.This unflinching perseverance towards quality has helped the company to earn enormous goodwill & trust, both from medical profession and pharmaceutical trade.

Being in partnership with the world means respecting its resources without compromise and so at Ortin, continuous process evaluation and monitoring waste recoveries ensure that the focus is maintained. Specialized facilities have helped us to earn a reputation for the expert handling of hazardous materials in the form of reactants and products. Teams from the ministry of health regularly inspect the company's plant. Every care is taken for treatment of solid wasters, discharged liquids and atmospheric releases.

Ortin is contemplating an entry into the OTC segment as part of its long term growth strategy. It is channeling its efforts towards building an overseas marketing network in order to enhance exports to third world countries. Ortin proposes to be certified as a WHO GMP Unit and to launch innovative Biotechnology products in Orthopedic and Dental Segments. The success behind them is only the Reliance which they carry for their Quality from the people all over the country. Their motto, right from their inception has been towards Quality and they still maintain them and continue to do so in future.

Products manufactured by the company include:

  • Capsules
  • Syrups / Dry syrups
  • Powders
  • Second Division Products
  • Generic Products

Achievements/ recognition :

  • Ortin has been certified as an ISO 9001: 2000 company by the internationally recognized Quality Management Certification Body, the National Quality Assurance, UK in pursuance of its focus towards Quality with its Policy to enhance customer satisfaction by providing Quality Pharmaceutical Formulations at optimum cost and maintain profitability through continual improvement of Quality Management Sytems and cGMP.
  • Ortin is honored as a registered Supplier of Drugs & Medicines with the most reputed Central, State & Quasi-Government Organizations & Institutions of our Country such as the Railways, Health Ministry, Defence, Posts & Telegraph, Electricity Hospitals, Transport Organizations, Research Institutions such as JIPMER, IICT etc.
Read More Read Less